Khan Najat 4

What Happened
Najat Khan, CEO, President and a director of Recursion Pharmaceuticals (RXRX), sold 23,588 shares on June 5, 2026. The weighted average sale price was $3.58 per share, for total proceeds of approximately $84,459. This was a disposition (sale), which is often routine and, in this case, occurred under a prearranged trading plan.

Key Details

• Transaction date: 2026-06-05 (filed same day). Transaction code: S (sale).
• Prices: executed in multiple trades at $3.56–$3.62; reported weighted average $3.58.
• Total shares sold: 23,588; total proceeds reported: $84,459.
• Shares owned after transaction: not disclosed in the provided filing.
• Footnotes: (1) Sale pursuant to a Rule 10b5-1 trading plan adopted Sept 22, 2025. (2) Multiple trade prices; issuer/SEC/security holders may request a breakdown of shares sold at each price.
• Filing timeliness: transaction and Form 4 were reported on the same date — not indicated as late.

Context
Sales executed under a Rule 10b5-1 plan are preplanned transactions that insiders use to avoid timing issues; they do not, by themselves, indicate a change in the insider’s view of the company. For retail investors, purchases typically carry more informational weight than routine sales; this transaction is a modest-dollar sale by the CEO executed via a 10b5-1 plan.